Shifts in the way Congress and
the White House talk about the drug industry in recent months have created an
opportunity for change that biotech and pharma companies, patient advocates and
investors should quickly seize.
The conversation has moved from
agonizing over how to regulate all risks out of drugs - an impossible goal - to
how better regulation can stimulate the creation of new, highly effective
medicines for patients with serious unmet needs.